Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Variation in the Treatment of Multiple Myeloma in the Real World

Joshua Richter, MD, Leena Chhun, B.S., Cheng Zheng, B.S., Jayne Piboonvaranggoon, B.S., Elora Mallick, B.S., Jennifer Wren, B.S., Grace Nam, M.S., Ricardo Lopez Barquilla, PhD, Alexandra Dardac, B.S., Sibel Blau, MD, Francis M. Senecal, MD, Swathi Namburi, MD, Andrew J. Cowan, MD, William I Bensinger, MD, Shaji K. Kumar, MD, Paul G. Richardson, MD, Kenneth Anderson, MD, C. Anthony Blau, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-138705

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Abdul Hamid Bazarbachi, MD, Herve Avet-Loiseau, Zachary R Hunter, PhD, Raphael Szalat, Anil Aktas-Samur, PhD, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Mariateresa Fulciniti, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Steven Treon, Mohamad Mohty, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138951

Published: 2020

Journal Articles

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao, Woojun D Park, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Nicholas P Kwiatkowski, PhD, Yan Xu, MD, Chandraditya Chakraborty, PhD, Behnam Nabet, PhD, Marta Chesi, PhD, Herve Avet-Loiseau, Nathaniel Gray, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Nikhil C. Munshi, MD, Mariateresa Fulciniti, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142592

Published: 2020

Journal Articles

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma

Arghya Ray, PhD, Ting DU, PhD, Krishan Chauhan, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-143393

Published: 2020

Journal Articles

Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

Sophia Adamia, PhD, Shruti Bhatt, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Catherine A Nicholas, Marissa S Pioso, Ivane Abiatari, MD, Anthony G. Letai, MD PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142596

Published: 2020

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

Chandraditya Chakraborty, PhD, Yan Xu, MD, Yao Yao, Eugenio Morelli, MD, Anil Aktas-Samur, PhD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD, Chandraditya Chakraborty, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142655

Published: 2020

Journal Articles

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Arghya Ray, PhD, Yan Song, PhD, Ting DU, PhD, Clifton C. Mo, MD, Arturo Olguin, Janice Chen, PhD, Christopher Brooks, PhD, Tariq I. Mughal, MD FRCP, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141571

Published: 2020

Journal Articles

Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Krishan Chauhan, Mehmet K. Samur, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-139966

Published: 2020

Journal Articles

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Chandraditya Chakraborty, PhD, Eugenio Morelli, MD, Srikanth Talluri, PhD, Sanika Derebail, MS, Yan Xu, MD, Yao Yao, María Linares, Alba Rodríguez García, Kenneth Anderson, MD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-142178

Published: 2020

Journal Articles

Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

William A. Wood, MD MPH, Donna S. Neuberg, ScD, John Colton Thompson, Martin S. Tallman, MD, Mikkael A. Sekeres, MD MS, Laurie H. Sehn, MDMPH, Kenneth Anderson, MD, Aaron D Goldberg, MDPhD, Nathan A Pennell, MD PhD, Charlotte M. Niemeyer, MD, Emily Tucker, MS, Kathleen Hewitt, DNP,CPHQ,AACC,RN, Robert M Plovnick, MD MS, Lisa K. Hicks, MD MSc

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141327

Published: 2020

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Annamaria Gulla, MD, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Cirino Botta, MDPhD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Stefano Malvestiti, MD, Rao Prabhala, Srikanth Talluri, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Paul G. Richardson, MD, Ruben D. Carrasco, MD PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140356

Published: 2020

Journal Articles

Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity

Arghya Ray, PhD, Ting DU, PhD, Yan Song, PhD, Sara J Buhrlage, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138591

Published: 2020

Journal Articles

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Anil Aktas-Samur, PhD, Abdul Hamid Bazarbachi, MD, Yu-Tzu Tai, PhD, Timothy B. Campbell, MD PhD, Fabio Petrocca, MD, Kristen Hege, MD, Shari Kaiser, PhD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-139040

Published: 2020

Journal Articles

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-134538

Published: 2020

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-141549

Published: 2020

Journal Articles

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136824

Published: 2020

Journal Articles

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Su Wang, PhD, Daisuke Ogiya, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth Wen, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-139778

Published: 2020

NARROW

Variation in the Treatment of Multiple Myeloma in the Real World

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma

Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only